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Abstract: The cytotoxicity of organometallic compounds iron(III)-, cobalt(III)-, manganese(II)-, and 
copper(II)-salophene (-SP) on platinum-resistant ovarian cancer cell lines was compared. Fe-SP 
displayed selective cytotoxicity (IC
50
 at ∼1 μM) against SKOV-3 and OVCAR-3 cell lines while 
Co-SP caused cytotoxic effects only at higher concentrations (IC
50
 at 60 μM) and Cu-SP effects 
were negligible. High cytotoxicity of Mn-SP (30–60 μM) appeared to be nonspeciﬁ c because 
the Mn-chloride salt reduced cell viability similarly. The effect of Fe-SP at 1 μM proved to 
be ovarian cancer cell selective when compared to a panel of cell lines derived from different 
tumors. The ﬁ rst irreversible step in the induction of cell death by Fe-SP occurred after 3 hrs 
as indicated by the mitochondrial transmembrane potential (ΔΨm) and was mainly linked to 
apoptotic, not necrotic events. To evaluate the toxicity of Fe-SP in vivo we conducted an acute 
toxicity study in rats. The LD
50
 of Fe-SP is 2000 mg/kg orally and 5.5 mg/kg body weight 
by intraperitoneal injection. An ovarian cancer animal model showed that the chemotherapeutic 
relevant dose of Fe-SP in rats is 0.5–1 mg/kg body weight. The present report suggests that 
Fe-SP is a potential therapeutic drug to treat ovarian cancer.
Keywords: iron(III)-salophene, chemotherapeutic properties, p38 MAPK, ovarian cancer 
animal model
Introduction
The current treatment of a variety of tumors, including ovarian cancer, relies on 
organometallic platinum compounds. In 2007, ovarian cancer was the leading cause 
of death (15,280 cases) from gynecologic malignancies and ranks second (22,430) 
among newly diagnosed gynecological cancers in the United States.1,2 Although most 
patients (70%–80%) initially respond to cytoreductive surgery and adjuvant paclitaxel 
and platinum-based chemotherapy, the majority will experience disease recurrence.3–5 
While re-treatment with a platinum-based drug is possible for some women, the 
response rate to current second or third line chemotherapy is below 33% mainly 
due to drug resistance.6–8 The mechanism of platinum resistance appears to include 
decreased cellular uptake, increased efﬂ ux, improved DNA repair, and prevention of 
DNA cross-linking.9,10 Likely candidates for platinum alternatives fall into the category 
of metal compounds.8,11,12
The design of new metal-based drugs is often challenged by physiochemical 
properties and ultimately their speciﬁ c effects in vivo. One approach to control 
the cytotoxic responses of metal-based compounds is to engage biologically 
essential transition metals, such as iron (Fe), manganese (Mn), copper (Cu), or 
cobalt (Co).11–13 In a recent study, we suggested that organometallic compound 
iron(III)-salophene (Fe-SP) displays properties that may assist in the treatment 
of ovarian cancer.14 Salophenes represent a class of organic compounds deﬁ ned 
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by two Schiff’s bases connecting three aromatic moieties 
that offer potent binding with transition metals and are 
closely related to salens which also contain Schiff’s bases 
that are constituted of aliphatic diamines. In our previous 
study Fe-SP displayed cytotoxic activity against ovarian 
adenocarcinoma cell lines at concentrations which did 
not affect primary ﬁ broblasts (0.1–1 μM).14 In addition, 
treatment with Fe-SP revealed morphological hallmarks of 
apoptosis and chromatin fragmentation in SKOV-3 cells, 
caused activation of markers of apoptosis and arrest of cell 
cycle progression in S-phase.14 Furthermore, Fe-SP did not 
show systemic toxicity in mice at concentrations that in 
the present manuscript are shown to be chemotherapeutic 
relevant doses in a rat ovarian cancer cell model.14 Based 
on our studies a patent was ﬁ led. This invention comprises 
the synthesis, biological applications, and pharmaceuti-
cal compositions of metal-salophenes (MSPs) and their 
use as therapeutic anti-neoplastic, anti-angiogenic and 
anti-cancer drugs.
The objective of the present study was to compare the 
cytotoxicity of Fe(III) vs cobalt(III), manganese (II), or cop-
per (II) as chloride-salts or when complexed with SP on ovarian 
cancer cell lines. We compared the cytotoxic effect of Fe-SP 
on ovarian cancer cells to a panel of cell lines derived from 
other solid tumors. An evaluation of the events leading to cell 
death was conducted by performing a mitochondrial membrane 
depolarization assay, a dose/time-dependent study of the 
kinetics of cytotoxic action by Fe-SP, by analysis via FACS 
of necrotic vs apoptotic events and of activation of apoptotic 
markers in vivo (rat model; IP treatment with Fe-SP). An acute 
toxicity study is presented along with an efﬁ cacy study of Fe-
SP in a rat ovarian cancer cell model. The present report sug-
gests that the novel organometallic compound Fe-SP induces 
ovarian cancer cell death by apoptosis in vitro and in vivo and 
at sub-toxic concentrations displays properties as a potential 
therapeutic drug in the treatment of ovarian cancer.
Materials and methods
Synthesis of salophene
The synthesis of the salophene ligand (SP, Figure 1A) 
followed a previously reported procedure.14,15 1,2-phenyl-
enediamine (1.24 g, 11.5 mmol) was added to a solution of 
o-vanillin (3.5 g, 23 mmol) in anhydrous ethanol (20 mL) and 
the yellowish solution stirred and reﬂ uxed for 2 h. The red-
dish suspension was ﬁ ltered and re-crystallized with boiling 
ethanol and the resultant reddish needles collected and dried 
(2.8 g SP, 65% yield). Salophene complexes were prepared 
as follows: SP (1.46 mmol) dissolved in acetone (44 mL) was 
carefully combined with 1.46 mmol of the respective chloride 
salts (FeCl
3
, CuCl
2
, Cl
3
CoH
18
N
6
, MnCl
2
) dissolved in acetone 
(5.5 mL). The resultant microcrystalline solids that grew in 
solution were ﬁ ltered, washed thoroughly with acetone, and 
dried to obtain the Me-SP complex which were dissolved in 
DMSO (dimethyl sulfoxide) for experiments in tissue culture 
and characterized by HPLC and X-ray crystallography14 with 
a high resolution X-ray diffraction system (Bruker SMART 
diffractometer using SHELXTL-97 software; Bruker AXS 
Inc., Madison, WI).
Cell culture
Human cell lines SKOV-3 (ovarian adenocarcinoma), 
OVCAR-3 (ovarian epithelial adenocarcinoma), CaOV-3 
(ovarian adenocarcinoma), A-431 (epidermoid skin 
carcinoma), PC-3 (prostate adenocarcinoma), LNCaP 
(prostate carcinoma), and BxPC-3 (pancreatic adenocar-
cinoma SH-SY5Y (neuroblastoma) were obtained from 
American Type Culture Collection (Manassas, VA). Cells 
were grown T75 cell culture ﬂ asks (Corning, New York, 
NY) in complete medium (Gibco, Rockville, MD) according 
to the suppliers recommendation. NUTU-19 rat epithelial 
ovarian cancer cells, a gift from Dr G. Scott Rose (Section 
of Gynecologic Oncology, Cleveland Clinic Foundation, 
Cleveland, OH) were cultured in RPMI 1640 supplemented 
with 10% fetal bovine serum, 100 U/mL penicillin, and 
100 μg/mL streptomycin. NUTU-19 cell line was derived 
from Fischer 344 rats.16
Cell viability assay
Viability of cells before and after drug treatment was deter-
mined was determined by the 96®Aqueous-One-Solution 
Assay (Promega, Madison, WI). The test was carried out 
as described previously.17 This colorimetric assay is based 
on the ability of mitochondria to reduce a substrate [MTS, 
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium] into a soluble formazan 
product quantiﬁ ed by measuring the absorbance at 490 nm. 
The resulting OD is directly proportional to the number of 
living cells.18 Brieﬂ y, cells (5 × 103/well) were plated into 
96 well ﬂ at bottom plates (Corning, Inc., Corning, NY) before 
treatment with various drugs or vehicle (DMSO) as indicated. 
Following incubation at 37 °C in a cell culture incubator for 
20 h MTS reagent was added at a 1:10 dilution to the medium. 
The samples were incubated for an additional 4 h before 
absorbance was measured at 490 nm in an ELISA plate 
reader (Thermo Labsystems, Waltham, MA). Experiments 
were performed in triplicates; data are expressed as the mean 
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of the triplicate determinations (X ± SD) of a representative 
experiment in % of absorbance by samples with untreated 
cells (=100%).
Mitochondrial transmembrane 
potential analysis
Cells (1 × 106) were seeded in a 100 mm petri-dish and treated 
with 1 μM of Fe-SP or SP for 3 h. After treatment the cells 
were washed with phosphate-buffer solution (PBS), resus-
pended in fresh medium (5 × 105 cells/mL) and incubated 
with 15 nM 3,3’-dioctadecyloxa-carbocyanine perchlorate 
(DiOC18(3); Invitrogen Eugene OR) for 30 min at 37 °C. The 
cells were washed twice with DPBS and measured by ﬂ ow 
cytometry (excitation, 488 nm; emission, 520 nm). Data was 
acquired on a BD FACSort ﬂ ow cytometer using CellQuest 
software (BD Immunocytometry-Systems, San Jose, CA) 
and analyzed (ModFit LT software, Verity Softwarehouse, 
Inc., Topsham, ME). Ten thousand cells were analyzed for 
each sample.
Determination of apoptotic and necrotic 
cells (by FACS)
The quantiﬁ cation of apoptotic cells was determined by 
combination staining with Annexin V and 7-Amino-
actinomycin (Apoptosis detection kit; BD Biosciences, San 
Jose, CA) allowing discrimination between early apoptotic 
cells (Annexin V positive), late apoptotic cells (Annexin 
V and 7-AAD positive), and necrotic cell death (7-AAD 
positive). Cells were seeded into 100 mm2 tissue culture 
dishes (5 × 105 cells/dish), treated (result section), ﬂ oating 
and attached cells combined, washed once with PBS, pH 7.4, 
(250 × g, 5 min) and stained. Analysis followed immediately 
on a Becton Dickinson (San Jose, CA) FACSCalibur; ten 
thousand events were analyzed for each sample, and gating 
was used to select the appropriate population of cells.
Animal toxicity study
Animal experiments were carried out in the animal facilities 
of Rhode Island Hospital (RIH), RI, USA with strict adher-
ence to the guidelines of the Animal Welfare Committee of 
RIH and Women and Infants Hospital.
The toxicity of Fe-SP in vivo was evaluated in rats (adult 
pathogen-free Fischer 344 female rats, weight, 100–150 g; 
Taconic, Germantown, NY) in a trial study following the “Up 
and Down Method” with Fe-SP applied by intra-peritoneal 
(IP) injection and by PO (oral gavage). The study was 
performed in compliance with OECD guideline 425 (see 
http://www.oecd.org/dataoecd/17/51/1948378.pdf; testing 
of chemicals, section 4: Health Effects Test No. 425). 
The objective of this study was to assess the acute toxicity 
of Fe-SP when administered in a single dose to rats intra-
peritoneally and orally at a deﬁ ned dose. Animals were 
randomly assigned to experimental groups (IP and PO 
groups, 7 in each group) and maintained at a temperature 
of 22 ± 1 °C and a relative humidity of 55% ± 5%, with a 
12 h light/dark cycle.
The amount of Fe-SP administered ranged from 
55–2000 mg/kg in the PO group and 5.5–17 mg/kg in 
the IP group. DMSO/PBS (20/80 v/v) stocks of Fe-SP 
were diluted 100-fold prior to administration to allow a 
constant dosage volume. Rats were administered Fe-SP 
by PO. The rats were fasted overnight prior to dosing and 
returned to feeding 3 h after dosing. On the day of dosing, 
all the animals were observed for signs of intoxication at 
30 min to 4 h following dosing and were observed twice 
a day for 14 days. Body weights of rats were individually 
recorded before dosing and at weekly intervals thereafter. 
All animals were sacriﬁ ced at the end of the observation 
period.
Animal (Rat) ovarian cancer model
Twenty rats in this therapeutic trial were divided into two 
treatment groups (0.5 or 1.0 mg Fe-SP/kg) of ﬁ ve animals 
each and one control group (10 animals). Brieﬂ y, NUTU-19 
cells were cultured to 80% conﬂ uence, harvested, counted 
for cell number and viability, and injected intra-peritoneal 
(IP) (1 × 106 cells in PBS). In this model, 100% of animals 
develop disease after three weeks. After three weeks daily 
intra-peritoneal injections of Fe-SP were administered 
at 0.5 and 1 mg/kg body weight. Vehicle (DMSO/PBS, 
20/80 v/v) was administered to the untreated control group. 
Animals were inspected daily for clinical condition and 
discomfort and pain per IACUC protocols. Food consump-
tion and body weights were be recorded weekly. All twenty 
animals were euthanized at the ﬁ fth week and tumor tissue 
was harvested.
Western blotting of tissue samples
Tumor tissue from all animals in a treatment group was 
collected and pooled, then weighed and diced into very 
small pieces using a clean razor blade. Three mL of ice 
cold lysis buffer (1% NP-40, 20 mM Tris pH 8.0, 137 mM 
NaCl, 10% glycerol, 2 mM EDTA, 1 mM activated sodium 
orthovanadate, 10 μg/mL Aprotinin, 10 μg/mL Leupeptin, 
Inhibitor Cocktail P-2714; Sigma-Aldrich, St. Louis, MO) 
were used per gram of tissue that was homogenized using 
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a sonicator (Sonic Dismembrator 100; Fisher Scientiﬁ c, 
Pittsburgh, PA; 4 watts output power, setting 10; 30 cycles 
of 5 sec each) while maintaining the samples on ice. The 
suspension was centrifuged at 10,000 g for 1 min at 4 °C 
and centrifugation of the supernatant repeated twice. The 
protein concentration of the remaining supernatant of the 
cell lysate was quantitated (BioRad protein estimation kit, 
Hercules, CA) and Western blotting was carried out as 
described previously17 and summarized here: samples were 
boiled in the presence of 5X SDS-PAGE sample buffer and 
50 μg total cellular protein/lane were separated on 12% 
SDS-polyacrylamide gels and blotted onto PVDF mem-
branes. The blots were blocked with 5% nonfat dry milk in 
PBST for 1 hr at room temperature and incubated overnight 
at 4 °C with the antibodies against Caspase-3 #9662 or 
cleaved PARP-1 #9541 (Cell Signaling Technology, Beverly, 
MA) at a 1:1000 dilution in 5% BSA in PBST on a rotating 
platform. After washing in PBST the blots were incubated 
with secondary antibody (peroxidase-conjugated antibodies; 
Amersham-Pharmacia Biotech, Piscataway, NJ). The bands 
were visualized using horseradish peroxidase-conjugated 
secondary antibodies (Amersham-Pharmacia Biotech, 
Piscataway, NJ) and documented by autoradiography 
(F-B × 810 Film, Phenix, Hayward, CA).
Statistical analyses
Means ± standard deviations (SD) were calculated. For 
animal experiments, mean hemorrhagic ascites volume 
and omental weight were compared between groups by 
ANOVA with Scheffe’s adjustment for multiple compari-
sons. Software used for these analyses was STATA version 
9.0 (Statacorp, College Station, TX).
Results
Specifi c cytotoxic effect of iron-salophene 
on human platinum-resistant ovarian 
cancer cell lines
In an initial approach to analyze the cytotoxic effects of 
various metal-salophene complexes on ovarian cancer cells 
we performed a viability assay employing SKOV-3 and 
OVCAR-3 ovarian cancer cell lines. The cells were treated 
for 24 h with various concentrations (0.1–60 μM) of either 
complexed salophene (Fe(III)-SP, Co(III)-SP Cu(II)-SP, 
Mn(II)-SP) or the respective metal chloride salts alone 
(Fe3+, Co3+, Cu2+, Mn2+). Treatment with noncomplexed 
salophene (SP), which did not signiﬁ cantly affect cell viability 
even at concentrations of 60 μM served as a negative control. 
Among these compounds only Fe-SP proved to be highly 
cytotoxic to SKOV-3 and OVCAR-3 cells (IC
50
 ∼1 μM) after 
24 h of treatment (Figure 1B). In contrast, Cu-SP did not sig-
niﬁ cantly reduce cell viability even at concentrations as high 
as 60 μM. Co-SP exerted speciﬁ c but only mildly cytotoxic 
effects on both cell lines tested (IC
50
 = 60 μM) when compared 
to either noncomplexed salophene or the respective Co-chlo-
ride salt alone. A relatively high cytotoxcicity of Mn-SP at 
concentrations of 30–60 μM was observed which, however, 
appeared to be unspeciﬁ c and solely linked to the presence 
of the Mn-ion since the Mn-chloride salt alone reduced cell 
viability almost identically to complexed Mn-SP.
We compared the cytotoxcicity of Fe-SP on ovarian 
cancer cell lines to the effect on the viability of other human 
cancer cell lines such as A-431 (epidermoid skin carcinoma), 
PC-3 (prostate adenocarcinoma), LNCaP (prostate carci-
noma), BxPC-3 (pancreatic adenocarcinoma), or SH-SY5Y 
(neuroblastoma) alongside with a third ovarian cancer cell 
line (CaOV-3, ovarian adenocarcinoma) (Figure 2). At con-
centrations above 3 μM Fe-SP was lethal to all cell lines 
other than the neuroblastoma cell line tested (IC
50
 = 3 μM). 
However, the cytotoxic effect of Fe-SP at 1 μM (IC
50
 for OC 
cells) was signiﬁ cantly lower for all nonovarian cancer cell 
lines as compared to platinum-resistant SKOV-3, OVCAR-3 
and CaOV-3 ovarian cancer cells. Noncomplexed salophene 
at 3 μM did not reduce the viability of any cell line treated 
(Figure 2, right panel).
Kinetics of the cytotoxic effects of Fe-SP; 
mitochondrial membrane depolarization, 
necrotic- and apoptotic population 
of SKOV-3 after Fe-SP treatment
Kinetic analysis of the viability of platinum-resistant SKOV-3 
cells revealed that the effect of Fe-SP treatment follows a 
dose- and time-dependent pattern (Figure 3). High cytotox-
icity could be observed for treatment at 5 and 10 μM Fe-SP 
within six hours reaching maximum responses within 12 h 
of treatment. At a Fe-SP concentration which selectively 
affects different cell lines (1 μM) (Figure 2)14 the response 
of SKOV-3 ovarian cancer cells needed 24–48 h to unfold 
(Figure 3).
In a ﬁ rst approach to understand the effect of Fe-SP on 
cellular functions we analyzed the integrity/loss of the mito-
chondrial transmembrane depolarization potential (ΔΨm) as 
determined by ﬂ uorescent staining with DiOC18(3) followed 
by FACS analysis (Figure 4A). Treatment of SKOV-3 ovarian 
cancer cells with the cell-selective concentration of 1 μM 
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Fe-SP resulted in a time-dependent increase in the number 
of cells with ΔΨm. Fluorescent staining with DiOC18(3) 
after Fe-SP treatment for 3 h, in contrast to nontreated or 
SP treated controls, revealed two populations of cells (two 
peaks in the FACS proﬁ le; Figure 4A, right panel). Fe-SP 
treatment led to a loss of the integrity of the Ψm in 40% of 
the population as compared to untreated cells (7.9%) or cells 
treated with parent compound SP (9.4%).
To determine the percentage of apoptotic versus necrotic 
cells after Fe-SP treatment FACS analysis was carried out. 
SKOV-3 cells were treated with 1 μM Fe-SP or noncom-
plexed SP for 24 h and ﬂ oating and attached cells collected 
and combined. The quantiﬁ cation of apoptotic cells was 
determined by staining with Annexin V and of necrotic cells 
by 7-AAD staining (see material and methods). Combination 
staining with both markers allowed discrimination between 
early apoptotic cells (Annexin V positive), late apoptotic 
cells (Annexin V and 7-AAD positive), and necrotic cell 
death (7-AAD positive). The assay revealed an apoptotic 
subpopulation of 77.8% (as determined by the combination 
of cells both in early and late apoptosis, Q4 + Q2; Figure 4B) 
for Fe-SP treated cells. In contrast only 10.8% of SP treated 
cells and 1.5% of nontreated cells underwent apoptosis. 
Necrosis was observed for 19.1% (Q1 + Q2; Figure 4B) of 
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Figure 1 Comparative analysis of the cytotoxic effect of various metallo-salophenes on platinum resistant ovarian cancer cell lines. (A) Structure of salophene ligand (SP) 
and metal-salophene complex (Me-SP). (B) Human ovarian cancer cells (SKOV-3, OVCAR-3) were treated for 24 h with various concentrations (0.1–60 μM) of either newly 
synthesized transition metal salophene complexes (Fe(III)-SP, Co(III)-SP, Mn(II)-SP, and Cu(II)-SP) or the respective metal chloride alone (Fe3+, Co3+, Mn2+, Cu2+) or the noncom-
plexed parent compound (SP). The MTS viability assay was carried out as described (Materials and methods). Experiments were performed in triplicates; data are expressed 
as the mean of the triplicate determinations (X ± SD) of a representative experiment in%cell viability of untreated cells (100%).
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Fe-SP treated cells (the majority of which, 13.4%, were in late 
apoptotic state; Q2) while necrosis remained at background 
levels in control cells (1.1%, resp. 2.2%, in SP-treated or 
nontreated cells; Figure 4B).
Chemotherapeutic treatment of ovarian 
tumor cells with Fe-SP in an animal 
ovarian cancer cell model
To evaluate the toxicity of Fe-SP in vivo we conducted an 
acute toxicity study with Fe-SP applied in a single dose by 
intra-peritoneal (IP) injection or by PO (gavage) (Table 1). 
Fe-SP, at the limit dose level of 2000 mg/kg body weight PO 
and 5.5 mg/kg IP, did not cause any mortality and did not 
induce any signs of toxicity in the treated female rats follow-
ing dosing and during the observation period (14 days). The 
body weight gain of treated rats was not found to be adversely 
affected. Based on these results and under the conditions of 
this study, the median lethal dose (LD
50
) of Fe-SP after single 
oral administration in female Fisher 344 rats was found to be 
(Table 1) 2000 mg/kg by PO (left panel) and 5.5 mg/kg 
body weight by IP (right panel).
To study the chemotherapeutic potential of Fe-SP in vivo 
an ovarian cancer model with rat ovarian NUTU-19 cancer 
cells injected by IP into rats was chosen. First we performed 
an in vitro viability assay on NUTU-19 cells which conﬁ rmed 
that Fe-SP but not SP lead to cell death (Figure 5A) as 
observed for the human ovarian cancer cell lines (SKOV-3, 
OVCAR-3, CaOV-3; Figure 2), though at higher concentra-
tions. To determine the chemotherapeutic relevant doses of 
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Figure 2 Differential effect of Fe-SP on the viability of various human cancer cells. The cytotoxic effect of Fe-SP (0–3 μM) on human ovarian cancer cells (SKOV-3, OVCAR-3, 
CaOV-3) was compared to various human cancer cell lines of different origin (LNCaP, PC-3, BxPC-3, A-431, SH-SY5Y). Treatment with 3 μM SP served as a negative control. 
The MTS viability assay was carried out as described (Materials and methods).
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Figure 3 Kinetics of the cytotoxic effect of Fe-SP on SKOV-3 ovarian cancer cells. 
SKOV-3 cells were treated with various concentrations (0–10 μM) of Fe-SP for 3, 6, 
12, 24, or 48 h. The MTS viability assay was carried out as described (Materials and 
methods).
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Fe-SP NUTU-19 cells were injected and three weeks after 
development of tumors (to mimic the situation following 
cytoreductive surgery) animals were either left untreated 
(10 animals) or treated daily with Fe-SP (0.5 or 1 mg/kg 
body weight, ﬁ ve animals in each group) via IP. Duration of 
treatment lasted 12 days and was based on tumor burden in 
the control animals. Western blotting conﬁ rmed activation of 
effector caspase-3 and inactivation of PARP-1 (involved in 
DNA repair) in tumor tissue after Fe-SP treatment (0.5 and 
1 mg/kg body weight) of the animals but not in tumor tissue 
of untreated animals (Figure 5B). This directly mirrors the 
induction of apoptosis observed in human ovarian cancer 
cells in vitro.14 Control animals showed a consistently 
elevated amount of hemorrhagic ascites. In contrast, treated 
animals displayed signiﬁ cantly less hemorrhagic ascites vol-
ume (Figure 5C) with a response in 70% (7 of 10) of animals 
treated: 40% of animals (one in the 0.5 mg/kg group and 
three in the 1.0 mg/kg group) displayed a complete response 
with no residual hemorrhagic ascites and no visible tumor 
(Figure 5D, example image shown). An additional 30% of 
animals treated (two in the 0.5 mg/kg group and one in the 
1.0 mg/kg group) displayed a partial response. In addition, 
omental weight in the Fe-SP treatment group was consis-
tently decreased in Fe-SP-treated animals versus nontreated 
controls (Figure 5C).
Discussion
A low survival rate for woman suffering from ovarian cancer 
is related to the development of resistance of tumor cells 
to standard platinum-derived chemotherapeutic agents and 
therefore new anti-cancer drugs need to be developed.2,4,8 
Transition metal salophene complexes are candidate agents 
for treatment of ovarian cancer.14
To compare the cytotoxicity of Fe(III)-salophene, 
Co(III)-, Mn(II)-, and Co(II)-salophene (-SP) we chose two 
ovarian adenocarcinoma cell lines (OVCAR-3; SKOV-3) 
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Figure 4 Determination of mitochondrial membrane depolarization, apoptotic and necrotic SKOV-3 cells after Fe-SP treatment. (A) Mitochondrial membrane depolarization 
analysis. SKOV-3 cells were treated for 3 h with 3 μM Fe-SP or SP control, fi xed and stained with DiOC18(3) as described (Materials and methods). Fluorescence of the single 
cell population was measured by fl ow cytometry (right panel) and the transmembrane depolarization potential of the single cell populations plotted (bar chart, left panel). Ten 
thousand cells were analyzed in each sample. (B) Apoptotic and necrotic cell population. SKOV-3 cells were treated with 1 μM Fe-SP or SP control for 24 h and fl oating and 
attached cells collected and combined. The quantifi cation of apoptotic cells (Annexin V plasma membrane staining) and necrotic cells (7-AAD DNA staining) of SKOV-3 cells 
was carried out by fl ow cytometry as described (see Materials and methods). Ten thousand events were analyzed for each sample.
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Table 1 Acute toxicity of iron salophene
PO administration Up and Down Method (UDM) as per OECD 
guideline 425
IP administration Up and Down Method (UDM) as per 
OECD guideline 425
Animal # Dose (mg/kg) Outcome LD50 (PO) Animal # Dose (mg/kg) Outcome LD50 (IP)
1 55 O 1 17.5 X
2 175 o 2 5.5 O
3 550 o 3 17.5 X 5.5 mg/Kg
4 2000 o 2000 mg/Kg 4 5.5 o
5 2000 o 5 17.5 X
6 2000 o 6 5.5 o
7 2000 o
Notes: O, No Response; X, Death within 2–14 days.
that are multi-drug resistant (see http://www.atcc.org). For 
a subsequent study of the selective cytotoxicity of the most 
effective salophene complex (Fe-SP) within a panel of cell 
lines of different tumor origin we added a third ovarian 
adenocarcinoma cell line (CaOV-3, resistant to cisplatin19, 
two human adenocarcinoma cell lines (PC-3/prostate tumor; 
BxPC-3/pancreatic tumor) and an epidermoid skin carcinoma 
line (A-431); a prostate carcinoma line (LNCaP) and a neuro-
blastoma line (SH-SY5Y). Previously, we showed that Fe-SP 
at 1 μM caused selective cytotoxicity and apoptosis in SKOV-3 
cells when compared to primary ﬁ broblasts which did not show 
altered growth or morphology at this concentration of Fe-SP.14 
In contrast to ﬁ broblasts, all the nonovarian cell lines studied 
here responded to Fe-SP at 1 μM. However, it was apparent 
that their viability was less affected than of all three ovarian 
cancer cell lines tested here indicating a dose-dependent and 
selective cytotoxicity of Fe-SP with ovarian cancer cells 
being more sensitive to treatment in vitro. More importantly, 
our trial study in an animal ovarian cancer model suggested 
that tumors in rats derived from ovarian cancer cells recede 
upon Fe-SP treatment, while no systemic toxicity in treated 
animals was detected.
The present state of research in the ﬁ eld of organometallic 
compounds such as salophenes or salens (related compound, 
see introduction) allows us to only speculate on the possible 
mechanism(s) of cytotoxic action of Fe-SP in cancer cells. 
A remarkable feature of metallo-salens, not yet analyzed for 
salophenes, is their afﬁ nity to a variety of aromatic neutral 
molecules; 20,21 salens when complexed with transition met-
als act as artiﬁ cial nucleases. Their reactivity in plasmid 
DNA cleavage assays can be controlled by conjugation or 
by the type and charge of the central metal ion core.22,23 For 
example, Ni(II)- or Mn(II)-salens were found to efﬁ ciently 
induce DNA strand scission22,24 but not of Fe(II)-salens 
unless hydroxyl groups facilitate their oxidation to Fe(III) 
species.23 Accordingly, in the present report we observed a 
high cytotoxicity and induction of apoptosis by the Fe(III)-SP 
complex. However, the cytotoxicity of Mn(III)-SP observed 
here was not complex-speciﬁ c but similar to treatment with 
the respective chloride-salt. Thus, for Mn-SP, involvement 
of DNA cleavage mechanisms did not appear to be essential 
in cell death of SKOV-3 or OVCAR-3. It has been postu-
lated that Fe-salen in cooperation with the quinine system 
facilitates the formation of iron(III) O
2
- species to produce 
free hydroxy radicals responsible for DNA cleavage.25 The 
DNA cleavage activity of Fe(III)-salen is partially linked to 
high water-solubility and charge24 which also likely applies 
to Fe(III)-SP. The cytotoxicity observed for Fe(III)-SP may 
follow the same mechanism known for Fe(III)-salen (similar 
charge mainly due to the metal-core). However, cell death 
induced by Fe-SP occurs with a 15–50-fold (depending on 
the cell line used) higher efﬁ ciency (Figure 2).14,24 In all three 
studies the same viability assay was employed.
Our previous data14 suggested that Fe-SP treatment 
affected cell-cycle checkpoints of SKOV-3 cells in S-phase. 
Targeting cell cycle checkpoints has been proposed as an 
alternative approach to anti-cancer therapies.26–28 While the 
mechanism of the cytotoxic effect of salens or Fe-SP on 
cells in culture or in vivo remains to be investigated, selec-
tive induction of apoptosis after drug treatment in vitro is a 
ﬁ rst indicator for potential effects on tumor metastasis and 
cell physiology in vivo. Fe-SP caused apoptosis in SKOV-3 
cells14 and in vivo (present study). Within 3 h of Fe-SP treat-
ment we observed a loss of mitochondrial transmembrane 
depolarization potential (ΔΨm) in SKOV-3 cells. The loss 
of ΔΨm due to chemical agents for other drug-treated cell 
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Figure 5 Chemotherapeutic effect of Fe-SP in an animal ovarian cancer cell model. (A) Effect of Fe-SP on the viability of rat ovarian cancer cells (NUTU-19) in vitro. Rat ovarian 
cancer cells (NUTU-19) were plated into 96 well fl at bottom plates and treated with various concentrations (0.5–4 μM) of Fe-SP or 4 μM noncomplexed SP. The MTS viability 
assay was carried out as described (Materials and Methods). (B) In vivo activation of Caspase-3 and in-activation of PARP-1 in ovarian cancer cell-derived tumors after Fe-SP 
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types has been reported to be indicator of early apoptosis and 
as the ﬁ rst irreversible step in the induction of apoptosis.29,30 
Accordingly, loss of the ΔΨm within 3 h in SKOV-3 follow-
ing Fe-SP treatment as seen here may be the ﬁ rst irreversible 
apoptotic event triggered by this agent. Previously, induc-
tion of apoptosis was shown to contribute to cell death of 
hEK293 (human kidney cells) upon Fe(III)-salen treatment.24 
To date, no further studies to the morphology and apoptotic 
signaling of any cell lines after treatment with compounds 
falling into the class of iron-salens or -salophenes have been 
published.
To set the stage for further investigation of Fe-SP as a poten-
tial therapeutic drug in addition to these in vitro studies we con-
ducted a study on the systemic toxicity of Fe-SP when applied 
in rats as a model system. When applied in rats Fe-SP neither 
revealed acute toxicity (at concentrations  5.5 mg/kg for IP 
administration, 2000 mg/kg for oral administration; present 
study) nor systemic toxicity (at concentrations  4 mg/kg14) that 
all exceeded the chemotherapeutic relevant doses (1 mg/kg 
body weight) of Fe-SP determined in the study trial presented 
here in a rat ovarian cancer cell model. In tumors of Fe-SP 
treated animals, but not in tumors of untreated rats, apoptotic 
events, such as caspase-3 activation and PARP deactivation 
occurred. The present report suggests that Fe-SP is a potent 
growth-suppressing agent in vitro for cell lines derived from 
ovarian cancer and a potential therapeutic drug to treat such 
tumors in vivo.
Disclosure
The authors declare no conﬂ icts of interest in this work.
References
 1. Heintz APM, Odicino F, Maisonneuve P, Beller U, Benedet JL, 
Creasman WT. International Federation of Gynecology and Obstet-
rics 25th Annual Report. Carcinoma of the Ovary. Int J Gyn Obst. 
2003;83:135–137.
 2. American Cancer Society. Cancer facts and ﬁ gures. 2007. Cited on 
Nov 6, 2008. Available from http://www.cancer.org.
 3. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and 
cisplatin compared with paclitaxel and cisplatin in patients with stage III 
and stage IV ovarian cancer. N Engl J Med. 1996;334:1–6.
 4. McGuire WP, Ozols RF. Chemotherapy of advanced ovarian cancer. 
Semin Oncol. 1998;25:340–348.
 5. Piccart MJ, Bertelsen K, James K, et al. Randomized intergroup trial of 
cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with 
advanced epithelial ovarian cancer: three-year results. J Natl Cancer 
Inst. 2000;92:699–708.
 6. Leitao MM Jr, Hummer A, Dizon DS, et al. Platinum re-treatment of 
platinum-resistant ovarian cancer after non-platinum therapy. Gynecol 
Oncol. 2003;91:123–129.
 7. Lamberth E, Gregory WM, Nelstrop AE, Rustin GJ. Long-term survival 
in 463 women treated with platinum analogs for advanced epithelial 
carcinoma of the ovary: life expectancy compared to women of an age-
matched normal population. Int J Gynecol Cancer. 2004;14:772–778.
 8. Ott I, Gust R. Non platinum metal complexes as anti-cancer drugs. Arch 
Pharm. 2007;340:117–126.
 9. Andrews P, Howell S. Cellular pharmacology of cisplatin: perspectives 
on mechanisms of acquired resistance. Cancer Cell. 1990;2:35–43.
10. Horowitz N, Hua J, Gibb R, Mutch D, Herzog T. The role of topotecan 
for extending the platinum-free interval in recurrent ovarian cancer: an 
in vitro model. Gynecol Oncol. 2004;94:67–73.
11. Köpf-Maier P. Complexes of metals other than platinum as antitumour 
agents. Eur J Clin Pharmacol. 1994;47:1–16.
12. Huang R, Wallquist A, Covell DG. Anticancer metal compounds in 
NCI-s tumor-screening database: putative mode of action. Biochem 
Pharmacol. 2005;69:1009–1039.
13. Zhong X, Weih, Liu WS, Wang DQ, Wang X. The crystal structures of 
copper(II), manganese(II), and nickel(II) complexes of a (Z)-2-hydroxy-
N’-(2-oxoindolin-3-ylidene) benzohydrazide-potential antitumor 
agents. Bioorg Med Chem Lett. 2007;17:3774–3777.
14. Lange TS, Kim KK, Singh RK, Strongin RM, McCourt CK, Brard 
L. Iron(III)-salophene: An metallo-organic compound with selective 
cytotoxic and anti-proliferative properties in platinum-resistant ovarian 
cancer cells. PLOS One. 2008;3(e2303):1–10.
15. Bi C, Fan Y, Sun G, Zheng G, Zhang G. Synthesis and characterization 
of Ln(III) complexes with N,N’-p-phenylenebis-(o-vanillylideneimine). 
Syn React Inorg Met. 2001;31:219–225.
16. Rose GS, Tocco LM, Granger GA, et al. Development and characteriza-
tion of a clinically useful animal model of epithelial ovarian cancer in 
the Fischer 344 rat. Am J Obstet Gynecol. 1996;175:593–599.
17. Lange TS, Singh RK, Kim KK, et al. Anti-proliferative and pro-apop-
totic Properties of 3-Bromoacetoxy Calcidiol (B3CD) in high-Risk 
Neuroblastoma. Chem Biol Drug Design. 2007;70:302–310.
18. Malich G, Markovic B, Winder C. The sensitivity and speciﬁ city of 
the MTS tetrazolium assay for detecting the in vitro cytotoxicity of 
20 chemicals using human cell lines. Toxicology. 1997;124:179–192.
19. Hayakawa J, Ohmichi M, Kurachi H, et al. Inhibition of extracellular 
signal-regulated protein kinase or c-Jun N-terminal protein kinase 
cascade, differentially activated by cisplatin, sensitizes human ovarian 
cancer cell line. J Biol Chem. 1999;274:31648–31654.
20. Burrows CJ, Rokita SE. Recognition of guanine structure in nucleic 
acids by nickel complexes. Acc Chem Res. 1994;27:295–301.
21. Mandal SS, Varshney U, Bhattacharya S. Role of the central metal ion 
and ligand charge in the DNA binding and modiﬁ cation by metallosalen 
complexes. Bioconjugate Chem. 1997;8:798–812.
22. Routier S, Cotelle N, Catteau JP, et al. Salen-anthraquinone conjugates. 
Synthesis, DNA-binding and cleaving properties, effects on topoisom-
erases and cytotoxicity. Bioorg Med Chem. 1996;4:1185–1196.
23. Routier S, Bernier JL, Catteau JP, et al. Synthesis, DNA binding, 
and cleaving properties of an ellipticine-salen.copper conjugate. 
Bioconjugate Chem. 1997;8:789–792.
24. Woldemariam GA, Mandal SS. Iron(III)-salen damages DNA and 
induces apoptosis inhuman cells via mitochondrial pathway. J Inorg 
Biochem. 2008;102:740–747.
25. Routier, S Vezinh, Lamour E, Bernier JL, Catteau JP, Bailly C. DNA-
cleavage by hydroxy-salicylidene-ethylendiamine-iron complexes. Nucl 
Acid Res. 1999;27:4160–4166.
26. Shapiro GI, Harper JW. Anticancer drug targets: cell-cycle and check-
point control. J Clin Invest. 1999;104:1645–1653.
27. Gladden AB, Diehl JA. Cell-cycle progression without cyclin E/CDK2: 
breaking down the walls of dogma. Cancer Cell. 2003;4:160–162.
28. Mazumder S, DuPree EL, Almasan A. A dual role of cyclin E in cell 
proliferation and apoptosis may provide a target for cancer therapy. 
Curr Cancer Drug Targets. 2004;4:65–75.
29. Kim R, Emi M, Tanabe K, Murakami S, Uchida Y, Arihiro K. Regula-
tion and interplay of apoptotic and non-apoptotic cell death. J Pathol. 
2006;208:319–326.
30. Petit PX, Lecoeur H, Zorn E, Dauguet C, Mignotte B, Gougeon 
ML. Alterations in mitochondrial structure and function are early 
events of dexamethasone-induced thymocyte apoptosis. J Cell Biol. 
1995;130:157–167.
